Next Phase Newsletter

An investment management firm based in China manages multiple funds and is engaged in equity investment, asset management, merger and acquisition across several industries including healthcare. The firm’s healthcare portfolio includes leading pharmaceutical companies in China. The size of investment varies depending on the deal, but the firm is investing from a 1 billion RMB fund for healthcare. The firm is currently seeking equity investment and licensing opportunities in China and the US. The firm is looking for companies with a China angle and has experience helping companies obtain CFDA approval.

Within healthcare, the firm is interested in medical devices, IVD, medical equipment, home-care products, and other healthcare-related technologies. The firm considers products that have at least completed prototype. The firm prefers products that have already obtained FDA clearance or approval, but it is happy to work with companies who are ~1 year away from FDA approval as well. In terms of indication areas, the firm is interested in diseases with large market potential in China, including oncology, reproductive health, cardiovascular diseases, and diabetes and metabolic disorders.

The firm seeks to work with experienced teams with strong sector knowledge. The firm is looking for products with a China angle and may request distribution rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused venture capital firm has offices in USA and China. The firm manages both USD and RMB denominated funds and generally seeks to make equity investments into emerging life science companies in seed and venture stages; however, the fund also considers commercial-stage companies, depending on the opportunity. The investment size of the USD fund ranges from $5 – $25 million. For the RMB fund, typical investment size is RMB 30- RMB150 million. The firm currently focuses on China-based companies or overseas businesses with a China angle.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics, Biotech R&D Services, Medical Technology and Healthcare IT. The firm is agnostic to disease indications but is most interested in areas with large market potential, including Diabetes, Cardiovascular, Musculoskeletal System and Connective Tissue, Diseases of the Eye and Oncology. Rare diseases are generally less of interest. The firm is open to invest in both small molecules and biologics, and it looks for all classes of devices. The funds are most interested in companies in preclinical and early-clinical stage, but they are open to companies in late-clinical and growth stage, on a case-by-case basis.

The firm will only invest in private companies. The firm is looking to be an active investor, sometimes taking a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The Fund is a subsidiary of a Pharmaceutical Group, a diversified enterprise group headquartered in China with an annual revenue of ~$600M. The Fund has a USA office in Los Angeles, CA. The parent company incorporates the following ecosystems:

(1) Commercialization Platform Ecosystem: The company operates as a commercialization platform in China for global high-quality pharmaceuticals, health brand operations, wholesale distribution, and retail. The firm has a strong marketing network of over 12,000 large and medium-sized hospitals and 300,000 pharmacies, as well as hundreds of upstream enterprises.

(2) Health Finance: The Fund seeks to incubate innovative businesses in the healthcare industry by providing financial capital and industrial support. The firm has invested in smart healthcare, diagnostics, R&D and manufacturing, etc.

The firm is open to global opportunities that have strong China market potential.

The Fund is currently focused on late stage investment opportunities and partnerships; in the life sciences, the firm is most interested in oncology/immuno-oncology therapeutics, diagnostics and tools, and technologies that integrate AI. Within therapeutics, the firm will consider various modalities including cell & gene therapy. The firm does not completely rule out early-stage opportunities, as the firm may consider investing in more early stages in the near future and are very keen to exploring novel technologies across all stages of development.

The Fund does not have very specific company or management team requirements, but does require that they demonstrate strong market potential in China, as that is where the firm’s primary business activities are based in. The firm is able to leverage their resources to provide companies with regulatory and commercialization support. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

The Fund, founded in 2009, is a venture capital firm based in China. The firm makes early-growth stage investments, preferably from angel/seed to B), but will consider series C. The firm typically invests USD 1-30 million per company. The firm prefers to invest in companies based in China, but is open to outstanding Chinese-led companies based in the US and Canada. The firm is actively seeking new investment opportunities.

In the life sciences, the firm currently considers therapeutics and diagnostics in bone/joint diseases, renal diseases, autoimmune deasese, cancer, and fibrosis. The firm is especially interested in immunotherapy, gene editing, and stem cell therapy that have preclinical data. Clinical data is desired, but not required.

The firm typically seeks Chinese-led teams with strong technical expertise and industry experience. The firm may request a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

The Foundation has helped to organize, and is a General Partner of, the Venture Fund, a $350 million fund focused on pre-clinical, Phase I, Phase II, and Phase III investments. The Fund executed a first close by June 2018, and a second close by early 2019.

The Fund invests primarily within the United States, but have a small allocation for foreign investments.

Sector interests include drugs, medical devices, and novel approaches. The firm is also open to funding technologies designed to accelerate cancer research and drug development, such as novel drug discovery tools or algorithms. The firm finances projects from the early discovery stage through to Phase III clinical trials. The foundation considers projects in any type of cancer.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.